Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2055-0936
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era ; volume:2 ; number:1 ; day:27 ; month:9 ; year:2016 ; pages:1-7 ; date:12.2016
Tropical diseases, travel medicine and vaccines ; 2, Heft 1 (27.9.2016), 1-7, 12.2016

Urheber
Stevenson, Heather L.
Beteiligte Personen und Organisationen
Utay, Netanya S.
SpringerLink (Online service)

DOI
10.1186/s40794-016-0038-5
URN
urn:nbn:de:1111-2016102911153
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:51 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Stevenson, Heather L.
  • Utay, Netanya S.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV

Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV

Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process

Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals

Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment

Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

Verbundene Objekte